Cardlytics Announces Potential Pricing for IPO

By Chris Lange Updated Jan 12, 4:00AM EST · Published Jan 29, 10:35AM EST

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Cardlytics Announces Potential Pricing for IPO — © Thinkstock

Cardlytics has filed an amended S-1 form with the Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The Atlanta-based unicorn intends to price its shares in the range of $13 to $15, with an overallotment option for an additional 810,000 shares. At the maximum price, the entire offering is valued up to $93.15 million. The company intends to list its shares on the Nasdaq under the symbol CDLX.

The underwriters for the offering are Merrill Lynch, JPMorgan, Wells Fargo, SunTrust Robinson Humphrey, Raymond James, and KeyBanc.

According to the firm, Cardlytics makes marketing more relevant and measurable through its purchase intelligence platform. With purchase data from over 2,000 financial institutions, it has a secure view into where and when consumers are spending their money. By applying advanced analytics to this massive aggregation of purchase data, the firm makes it actionable, helping marketers identify, reach and influence likely buyers at scale, and measure the true sales impact of their marketing spend.

[nativounit]

This collection of debit, credit, ACH, and bill pay data represented roughly $1.3 trillion in U.S. consumer spend in 2016. In 2016, its platform analyzed over 18.0 billion online and in-store transactions across more than 94.0 million accounts in the United States, representing one in five debit and credit card swipes in the United States.

In terms of its finances, the company reported:

Our revenue, which excludes consumer incentives, was $53.8 million, $77.6 million and $112.8 million, for 2014, 2015 and 2016, respectively, representing a compound annual growth rate of 44.8%. Our revenue for the nine months ended September 30, 2017 was $91.1 million. For 2014, 2015, 2016 and the nine months ended September 30, 2017, our net loss was $38.9 million, $40.6 million, $75.7 million and $15.6 million, respectively.

Cardlytics intends to use the net proceeds from this offering for working capital and general corporate purposes.

[wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.